High-density lipoproteins neutralize C-reactive protein proinflammatory activity

C-reactive protein (CRP), a well-recognized marker of atherosclerosis, has recently been suggested to have a direct proinflammatory effect. The constitutive expression of low levels of CRP in normal plasma suggests the likelihood that a natural factor exists to neutralize the effect of CRP. This fac...

Full description

Saved in:
Bibliographic Details
Published inCirculation (New York, N.Y.) Vol. 109; no. 17; pp. 2116 - 2122
Main Authors WADHAM, Carol, ALBANESE, Nathaniel, ROBERTS, Jane, LIJUN WANG, BAGLEY, Christopher J, GAMBLE, Jennifer R, RYE, Kerry-Anne, BARTER, Philip J, VADAS, Mathew A, PU XIA
Format Journal Article
LanguageEnglish
Published Hagerstown, MD Lippincott Williams & Wilkins 04.05.2004
Subjects
Online AccessGet full text

Cover

Loading…
Abstract C-reactive protein (CRP), a well-recognized marker of atherosclerosis, has recently been suggested to have a direct proinflammatory effect. The constitutive expression of low levels of CRP in normal plasma suggests the likelihood that a natural factor exists to neutralize the effect of CRP. This factor(s) has not yet been identified. Method and Results- The proinflammatory effect of CRP was measured by the induction of inflammatory adhesion molecules in human umbilical vein endothelial cells (HUVECs). We show that CRP significantly induced upregulation of adhesion molecules in both protein and mRNA levels. The CRP-induced expression of these inflammatory adhesion molecules was completely suppressed when the cells were preincubated with a physiological concentration (1 mg/mL apolipoprotein A-I) of HDLs derived from human plasma (native HDL) or reconstituted HDL (rHDL) at a very low concentration (0.01 mg/mL apolipoprotein A-I). A novel mechanism of HDL inhibition is likely to operate, because (1) rHDL was 100 times more potent than native HDL, (2) preincubation with HDL and its sustained presence were obligatory, and (3) oxidized 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine was the fundamental active component. The CRP-induced upregulation of inflammatory adhesion molecules in HUVECs was completely prevented by HDL via their oxidized phospholipid components.
AbstractList BACKGROUNDC-reactive protein (CRP), a well-recognized marker of atherosclerosis, has recently been suggested to have a direct proinflammatory effect. The constitutive expression of low levels of CRP in normal plasma suggests the likelihood that a natural factor exists to neutralize the effect of CRP. This factor(s) has not yet been identified. Method and Results- The proinflammatory effect of CRP was measured by the induction of inflammatory adhesion molecules in human umbilical vein endothelial cells (HUVECs). We show that CRP significantly induced upregulation of adhesion molecules in both protein and mRNA levels. The CRP-induced expression of these inflammatory adhesion molecules was completely suppressed when the cells were preincubated with a physiological concentration (1 mg/mL apolipoprotein A-I) of HDLs derived from human plasma (native HDL) or reconstituted HDL (rHDL) at a very low concentration (0.01 mg/mL apolipoprotein A-I). A novel mechanism of HDL inhibition is likely to operate, because (1) rHDL was 100 times more potent than native HDL, (2) preincubation with HDL and its sustained presence were obligatory, and (3) oxidized 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine was the fundamental active component.CONCLUSIONSThe CRP-induced upregulation of inflammatory adhesion molecules in HUVECs was completely prevented by HDL via their oxidized phospholipid components.
C-reactive protein (CRP), a well-recognized marker of atherosclerosis, has recently been suggested to have a direct proinflammatory effect. The constitutive expression of low levels of CRP in normal plasma suggests the likelihood that a natural factor exists to neutralize the effect of CRP. This factor(s) has not yet been identified. Method and Results- The proinflammatory effect of CRP was measured by the induction of inflammatory adhesion molecules in human umbilical vein endothelial cells (HUVECs). We show that CRP significantly induced upregulation of adhesion molecules in both protein and mRNA levels. The CRP-induced expression of these inflammatory adhesion molecules was completely suppressed when the cells were preincubated with a physiological concentration (1 mg/mL apolipoprotein A-I) of HDLs derived from human plasma (native HDL) or reconstituted HDL (rHDL) at a very low concentration (0.01 mg/mL apolipoprotein A-I). A novel mechanism of HDL inhibition is likely to operate, because (1) rHDL was 100 times more potent than native HDL, (2) preincubation with HDL and its sustained presence were obligatory, and (3) oxidized 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine was the fundamental active component. The CRP-induced upregulation of inflammatory adhesion molecules in HUVECs was completely prevented by HDL via their oxidized phospholipid components.
Background— C-reactive protein (CRP), a well-recognized marker of atherosclerosis, has recently been suggested to have a direct proinflammatory effect. The constitutive expression of low levels of CRP in normal plasma suggests the likelihood that a natural factor exists to neutralize the effect of CRP. This factor(s) has not yet been identified. Method and Results— The proinflammatory effect of CRP was measured by the induction of inflammatory adhesion molecules in human umbilical vein endothelial cells (HUVECs). We show that CRP significantly induced upregulation of adhesion molecules in both protein and mRNA levels. The CRP-induced expression of these inflammatory adhesion molecules was completely suppressed when the cells were preincubated with a physiological concentration (1 mg/mL apolipoprotein A-I) of HDLs derived from human plasma (native HDL) or reconstituted HDL (rHDL) at a very low concentration (0.01 mg/mL apolipoprotein A-I). A novel mechanism of HDL inhibition is likely to operate, because (1) rHDL was 100 times more potent than native HDL, (2) preincubation with HDL and its sustained presence were obligatory, and (3) oxidized 1-palmitoyl-2-linoleoyl- sn -glycero-3-phosphocholine was the fundamental active component. Conclusions— The CRP-induced upregulation of inflammatory adhesion molecules in HUVECs was completely prevented by HDL via their oxidized phospholipid components.
Author BAGLEY, Christopher J
GAMBLE, Jennifer R
LIJUN WANG
RYE, Kerry-Anne
PU XIA
ALBANESE, Nathaniel
ROBERTS, Jane
WADHAM, Carol
BARTER, Philip J
VADAS, Mathew A
Author_xml – sequence: 1
  givenname: Carol
  surname: WADHAM
  fullname: WADHAM, Carol
  organization: Division of Human Immunology, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia
– sequence: 2
  givenname: Nathaniel
  surname: ALBANESE
  fullname: ALBANESE, Nathaniel
  organization: Division of Human Immunology, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia
– sequence: 3
  givenname: Jane
  surname: ROBERTS
  fullname: ROBERTS, Jane
  organization: Division of Human Immunology, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia
– sequence: 4
  surname: LIJUN WANG
  fullname: LIJUN WANG
  organization: Division of Human Immunology, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia
– sequence: 5
  givenname: Christopher J
  surname: BAGLEY
  fullname: BAGLEY, Christopher J
  organization: Division of Human Immunology, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia
– sequence: 6
  givenname: Jennifer R
  surname: GAMBLE
  fullname: GAMBLE, Jennifer R
  organization: Division of Human Immunology, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia
– sequence: 7
  givenname: Kerry-Anne
  surname: RYE
  fullname: RYE, Kerry-Anne
  organization: Lipid Research Group, The Heart Research Institute, Camperdown, NSW, Australia
– sequence: 8
  givenname: Philip J
  surname: BARTER
  fullname: BARTER, Philip J
  organization: Lipid Research Group, The Heart Research Institute, Camperdown, NSW, Australia
– sequence: 9
  givenname: Mathew A
  surname: VADAS
  fullname: VADAS, Mathew A
  organization: Division of Human Immunology, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia
– sequence: 10
  surname: PU XIA
  fullname: PU XIA
  organization: Division of Human Immunology, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15835560$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/15078800$$D View this record in MEDLINE/PubMed
BookMark eNpNkMlKBDEQQIMoOi6_II2gt26zp-NNBjcQFNFzyKQrGullTHqE8euNY4PWpSjq1cLbR9v90ANCJwRXhEhyjkk1v3uqcA5CFSe64kIrUVG5hWZEUF5ywfQ2mmVAl4pRuof2U3rPpWRK7KI9IrCqa4xn6PE2vL6VDfQpjOuiDcthGYcRQp-KHlZjtG34gmJeRrBuDJ9QTO2fHHrf2q6z4xDXxaaddxyiHW_bBEdTPkAv11fP89vy_uHmbn55XzqB5Vhy0jBPPadacMmVVVovQNhGW-qZchxL8NzKBjjTteLCu5oCk9JZsfBQE3aAzn735kc-VpBG04XkoG1tD8MqGUVqrXCtM3jxC7o4pBTBm2UMnY1rQ7D58WkwMdmn-fNpNj4NlXn4eLqyWnTQ_I1OAjNwOgE2Odv6aHsX0j-uZkJIzL4BtOKBrg
CODEN CIRCAZ
CitedBy_id crossref_primary_10_1097_00041433_200412000_00005
crossref_primary_10_1289_EHP2062
crossref_primary_10_4049_jimmunol_1001534
crossref_primary_10_1074_jbc_M608175200
crossref_primary_10_1157_13095098
crossref_primary_10_1016_j_metabol_2009_05_004
crossref_primary_10_31857_S0320972521100031
crossref_primary_10_1016_j_coi_2007_11_001
crossref_primary_10_1097_01_hco_0000184529_52832_e6
crossref_primary_10_1002_dmrr_2372
crossref_primary_10_1038_labinvest_2011_42
crossref_primary_10_1007_s00592_009_0150_3
crossref_primary_10_1016_j_cjca_2012_05_003
crossref_primary_10_1055_s_0041_1731273
crossref_primary_10_1194_jlr_M600227_JLR200
crossref_primary_10_1074_jbc_M512538200
crossref_primary_10_1038_oby_2010_114
crossref_primary_10_18699_SSMJ20220605
crossref_primary_10_3390_metabo11120874
crossref_primary_10_1134_S1990750818020075
crossref_primary_10_2147_IJGM_S324889
crossref_primary_10_1155_2022_2993309
crossref_primary_10_1007_s40572_014_0011_2
crossref_primary_10_1586_eci_10_98
crossref_primary_10_1371_journal_pone_0071235
crossref_primary_10_1007_s11745_009_3369_4
crossref_primary_10_1134_S1990519X23040090
crossref_primary_10_1134_S0006297921100047
crossref_primary_10_1089_jir_2019_0029
crossref_primary_10_2217_17460875_1_5_517
crossref_primary_10_1093_toxsci_kft130
crossref_primary_10_1515_cclm_2011_772
crossref_primary_10_1002_art_22201
crossref_primary_10_1016_j_atherosclerosis_2013_08_037
crossref_primary_10_1111_j_1538_7836_2008_03175_x
crossref_primary_10_1194_jlr_R400017_JLR200
crossref_primary_10_1038_ncpcardio0074
crossref_primary_10_1002_oby_20332
crossref_primary_10_1016_j_atherosclerosis_2005_10_032
crossref_primary_10_3390_biology11030430
crossref_primary_10_1097_00075197_200503000_00007
crossref_primary_10_1097_01_mol_0000169356_58513_25
crossref_primary_10_1016_j_atherosclerosis_2005_12_026
crossref_primary_10_1080_07853890500526352
crossref_primary_10_1007_s13340_011_0059_2
crossref_primary_10_1016_j_dci_2005_03_009
crossref_primary_10_1002_art_27447
crossref_primary_10_1002_clc_20692
crossref_primary_10_1097_MCI_0b013e32831550d9
crossref_primary_10_1016_j_biopha_2008_12_002
crossref_primary_10_1016_j_atherosclerosissup_2005_02_004
crossref_primary_10_2174_0929867326666190516103953
crossref_primary_10_3389_fendo_2023_1275132
crossref_primary_10_5551_jat_E571
crossref_primary_10_1021_acs_jproteome_5b00419
crossref_primary_10_3390_healthcare10101982
crossref_primary_10_1016_j_cca_2015_10_021
crossref_primary_10_1016_j_plipres_2012_03_003
crossref_primary_10_1007_s10654_017_0251_1
crossref_primary_10_1016_j_metabol_2010_04_018
crossref_primary_10_1016_j_rpth_2023_100063
crossref_primary_10_1016_j_imbio_2011_07_030
crossref_primary_10_1093_intimm_dxl023
crossref_primary_10_1111_j_0894_0959_2004_17604_x
crossref_primary_10_1016_j_actbio_2016_02_008
crossref_primary_10_1016_j_clinbiochem_2009_11_018
crossref_primary_10_1194_jlr_M800271_JLR200
crossref_primary_10_2310_JIM_0b013e31824e980c
crossref_primary_10_1038_s41598_022_07271_8
crossref_primary_10_1016_j_clinbiochem_2009_01_010
crossref_primary_10_1185_030079905X26216
crossref_primary_10_1111_j_1468_1331_2007_02026_x
crossref_primary_10_1007_s00281_009_0149_4
crossref_primary_10_1155_2012_181394
crossref_primary_10_1016_j_freeradbiomed_2017_07_032
crossref_primary_10_1097_HCO_0b013e3283043806
crossref_primary_10_18097_PBMC20186401066
crossref_primary_10_1152_ajpheart_01418_2006
crossref_primary_10_1016_j_ahj_2011_12_017
crossref_primary_10_1093_eurheartj_sui036
crossref_primary_10_1152_ajpheart_00067_2011
crossref_primary_10_1111_j_1440_1681_2009_05338_x
crossref_primary_10_1111_j_1365_2567_2006_02516_x
crossref_primary_10_1590_S0074_02762011000800014
crossref_primary_10_1016_S1131_3587_05_74096_6
crossref_primary_10_7793_jcoron_20_033
crossref_primary_10_1016_S0214_9168_08_72596_8
crossref_primary_10_1159_000090435
crossref_primary_10_1177_0961203306071668
crossref_primary_10_1007_s12010_011_9270_7
crossref_primary_10_1016_j_atherosclerosis_2009_05_034
crossref_primary_10_1371_journal_pone_0070533
crossref_primary_10_1016_S1131_3587_12_70040_7
crossref_primary_10_1093_eurheartj_sui044
crossref_primary_10_1097_TEN_0b013e3181a6a5ed
crossref_primary_10_1586_14779072_2014_896741
crossref_primary_10_1155_2013_186365
crossref_primary_10_2174_1568026620666200427091454
crossref_primary_10_1080_14017430701411234
crossref_primary_10_1016_j_amjmed_2012_02_013
crossref_primary_10_3390_biomedicines8120620
crossref_primary_10_1016_j_cbd_2018_10_001
crossref_primary_10_1016_j_ijcard_2006_11_010
crossref_primary_10_1111_j_1365_2796_2006_01608_x
crossref_primary_10_1128_IAI_00359_06
crossref_primary_10_1371_journal_pone_0116867
Cites_doi 10.1161/atvb.18.9.1450
10.1056/NEJM200003233421202
10.1016/S0022-2275(20)33434-9
10.1074/jbc.274.46.33143
10.1084/jem.190.4.585
10.1016/S0021-9150(00)00659-6
10.1161/01.cir.0000033116.22237.f9
10.1046/j.1365-2249.2000.01281.x
10.1016/0076-6879(86)28092-1
10.1038/nature01023
10.1161/01.cir.0000029802.88087.5e
10.1016/S0002-9149(01)01799-4
10.1161/circ.103.21.2531
10.1161/circ.102.18.2165
10.1161/01.CIR.104.2.145
10.1002/jcp.1040960209
10.1161/atvb.15.11.1987
10.1073/pnas.96.21.12010
10.1161/res.88.9.877
10.1016/S0021-9258(18)34756-2
10.1016/0952-7915(95)80029-8
10.1073/pnas.192399699
10.1016/0022-1759(94)90366-2
10.1002/1097-0320(20000701)40:3<238::AID-CYTO9>3.0.CO;2-3
10.4049/jimmunol.150.10.4494
10.1001/jama.285.19.2481
10.1046/j.1365-2249.1998.00597.x
ContentType Journal Article
Copyright 2004 INIST-CNRS
Copyright_xml – notice: 2004 INIST-CNRS
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1161/01.CIR.0000127419.45975.26
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 1524-4539
EndPage 2122
ExternalDocumentID 10_1161_01_CIR_0000127419_45975_26
15078800
15835560
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
.-D
.3C
.55
.GJ
.XZ
.Z2
01R
08R
0R~
0ZK
18M
1CY
1J1
29B
2FS
2WC
354
40H
41~
4Q1
4Q2
4Q3
53G
5GY
5RE
5VS
6PF
71W
77Y
7O~
AAAXR
AAEJM
AAGIX
AAHPQ
AAJCS
AAMOA
AAMTA
AAPBV
AAQKA
AARTV
AASOK
AASXQ
AAUGY
AAWTL
AAXQO
AAYOK
ABASU
ABBUW
ABDIG
ABOCM
ABPMR
ABPTK
ABQRW
ABXVJ
ABZAD
ACCJW
ACDDN
ACEWG
ACGFO
ACGFS
ACILI
ACOAL
ACRKK
ACRZS
ACWDW
ACWRI
ACXNZ
ADBBV
ADCYY
ADFPA
ADGGA
ADNKB
AE3
AE6
AEBDS
AEETU
AENEX
AFCHL
AFDTB
AFFNX
AFUWQ
AGINI
AHMBA
AHOMT
AHRYX
AHVBC
AIJEX
AJIOK
AJJEV
AJNWD
AJNYG
AKALU
AKULP
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
AOHHW
ASPBG
AVWKF
AWKKM
AYCSE
AZFZN
BAWUL
BOYCO
BQLVK
BS7
BYPQX
C1A
C45
CS3
DIK
DIWNM
DU5
DUNZO
E.X
E3Z
EBS
EEVPB
EJD
EX3
F2K
F2L
F2M
F2N
F5P
FCALG
FEDTE
FL-
FW0
GNXGY
GQDEL
GX1
H0~
H13
HZ~
H~9
IKREB
IKYAY
IN~
IPNFZ
IQODW
J5H
JF9
JG8
JK3
JK8
K-A
K-F
K8S
KD2
KMI
KQ8
L-C
L7B
M18
MVM
N4W
N9A
NEJ
N~7
N~B
N~M
O9-
OAG
OAH
OBH
OCB
OCUKA
ODA
ODMTH
OGEVE
OHH
OHT
OHYEH
OJAPA
OK1
OL1
OLB
OLG
OLH
OLU
OLV
OLW
OLY
OLZ
OPUJH
ORVUJ
OUVQU
OVD
OVDNE
OVIDH
OVLEI
OVOZU
OWBYB
OWU
OWV
OWW
OWX
OWY
OWZ
OXXIT
P-K
P2P
PQQKQ
R58
RAH
RHF
RIG
RLZ
S4R
S4S
T8P
TEORI
TR2
TSPGW
UPT
V2I
VVN
W2D
W3M
W8F
WH7
WHG
WOQ
WOW
X3V
X3W
X7M
XXN
XYM
YFH
YOC
YQJ
YSK
YXB
YYM
YYP
YZZ
ZA5
ZFV
ZGI
ZXP
ZY1
ZZMQN
~H1
AAAAV
AAIQE
AAUEB
ABJNI
ADHPY
AFEXH
AHQNM
AINUH
AJZMW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c506t-41d3f2f42954647a799be5ad9a2f37c406ef4a6de4398745fc82e366ca5bfe813
ISSN 0009-7322
IngestDate Fri Oct 25 06:04:49 EDT 2024
Fri Aug 23 01:12:42 EDT 2024
Tue Oct 15 23:27:43 EDT 2024
Sun Oct 22 16:06:03 EDT 2023
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 17
Keywords Vascular disease
Atherosclerosis
protein
Cardiovascular disease
Inflammation
Lipoprotein
C reactive protein
lipoproteins
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c506t-41d3f2f42954647a799be5ad9a2f37c406ef4a6de4398745fc82e366ca5bfe813
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ahajournals.org/doi/pdf/10.1161/01.CIR.0000127419.45975.26
PMID 15078800
PQID 71897089
PQPubID 23479
PageCount 7
ParticipantIDs proquest_miscellaneous_71897089
crossref_primary_10_1161_01_CIR_0000127419_45975_26
pubmed_primary_15078800
pascalfrancis_primary_15835560
PublicationCentury 2000
PublicationDate 2004-05-04
PublicationDateYYYYMMDD 2004-05-04
PublicationDate_xml – month: 05
  year: 2004
  text: 2004-05-04
  day: 04
PublicationDecade 2000
PublicationPlace Hagerstown, MD
PublicationPlace_xml – name: Hagerstown, MD
– name: United States
PublicationTitle Circulation (New York, N.Y.)
PublicationTitleAlternate Circulation
PublicationYear 2004
Publisher Lippincott Williams & Wilkins
Publisher_xml – name: Lippincott Williams & Wilkins
References e_1_3_3_17_2
e_1_3_3_16_2
e_1_3_3_19_2
e_1_3_3_18_2
e_1_3_3_13_2
e_1_3_3_12_2
e_1_3_3_15_2
e_1_3_3_14_2
e_1_3_3_11_2
e_1_3_3_10_2
e_1_3_3_6_2
e_1_3_3_5_2
e_1_3_3_8_2
e_1_3_3_7_2
e_1_3_3_9_2
e_1_3_3_27_2
e_1_3_3_24_2
e_1_3_3_23_2
e_1_3_3_26_2
e_1_3_3_25_2
e_1_3_3_2_2
e_1_3_3_20_2
e_1_3_3_1_2
e_1_3_3_4_2
e_1_3_3_22_2
e_1_3_3_3_2
e_1_3_3_21_2
References_xml – ident: e_1_3_3_13_2
  doi: 10.1161/atvb.18.9.1450
– ident: e_1_3_3_8_2
  doi: 10.1056/NEJM200003233421202
– ident: e_1_3_3_17_2
  doi: 10.1016/S0022-2275(20)33434-9
– ident: e_1_3_3_19_2
  doi: 10.1074/jbc.274.46.33143
– ident: e_1_3_3_23_2
  doi: 10.1084/jem.190.4.585
– ident: e_1_3_3_18_2
  doi: 10.1016/S0021-9150(00)00659-6
– ident: e_1_3_3_3_2
  doi: 10.1161/01.cir.0000033116.22237.f9
– ident: e_1_3_3_25_2
  doi: 10.1046/j.1365-2249.2000.01281.x
– ident: e_1_3_3_15_2
  doi: 10.1016/0076-6879(86)28092-1
– ident: e_1_3_3_22_2
  doi: 10.1038/nature01023
– ident: e_1_3_3_2_2
  doi: 10.1161/01.cir.0000029802.88087.5e
– ident: e_1_3_3_27_2
  doi: 10.1016/S0002-9149(01)01799-4
– ident: e_1_3_3_1_2
  doi: 10.1161/circ.103.21.2531
– ident: e_1_3_3_4_2
  doi: 10.1161/circ.102.18.2165
– ident: e_1_3_3_26_2
  doi: 10.1161/01.CIR.104.2.145
– ident: e_1_3_3_10_2
  doi: 10.1002/jcp.1040960209
– ident: e_1_3_3_7_2
  doi: 10.1161/atvb.15.11.1987
– ident: e_1_3_3_21_2
  doi: 10.1073/pnas.96.21.12010
– ident: e_1_3_3_6_2
  doi: 10.1161/res.88.9.877
– ident: e_1_3_3_14_2
  doi: 10.1016/S0021-9258(18)34756-2
– ident: e_1_3_3_5_2
  doi: 10.1016/0952-7915(95)80029-8
– ident: e_1_3_3_20_2
  doi: 10.1073/pnas.192399699
– ident: e_1_3_3_16_2
  doi: 10.1016/0022-1759(94)90366-2
– ident: e_1_3_3_12_2
  doi: 10.1002/1097-0320(20000701)40:3<238::AID-CYTO9>3.0.CO;2-3
– ident: e_1_3_3_11_2
  doi: 10.4049/jimmunol.150.10.4494
– ident: e_1_3_3_9_2
  doi: 10.1001/jama.285.19.2481
– ident: e_1_3_3_24_2
  doi: 10.1046/j.1365-2249.1998.00597.x
SSID ssj0006375
Score 2.22068
Snippet C-reactive protein (CRP), a well-recognized marker of atherosclerosis, has recently been suggested to have a direct proinflammatory effect. The constitutive...
Background— C-reactive protein (CRP), a well-recognized marker of atherosclerosis, has recently been suggested to have a direct proinflammatory effect. The...
BACKGROUNDC-reactive protein (CRP), a well-recognized marker of atherosclerosis, has recently been suggested to have a direct proinflammatory effect. The...
SourceID proquest
crossref
pubmed
pascalfrancis
SourceType Aggregation Database
Index Database
StartPage 2116
SubjectTerms Animals
Aorta
Biological and medical sciences
Blood and lymphatic vessels
C-Reactive Protein - antagonists & inhibitors
C-Reactive Protein - pharmacology
Cardiology. Vascular system
Cattle
Cell Adhesion
Cells, Cultured - drug effects
Cells, Cultured - metabolism
Culture Media, Conditioned - pharmacology
Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous
E-Selectin - biosynthesis
E-Selectin - genetics
Endothelial Cells - drug effects
Endothelial Cells - metabolism
Gene Expression Regulation - drug effects
Humans
Inflammation
Intercellular Adhesion Molecule-1 - biosynthesis
Intercellular Adhesion Molecule-1 - genetics
Lipoproteins, HDL - pharmacology
Liposomes - pharmacology
Medical sciences
Oxidation-Reduction
Phosphatidylcholines - pharmacology
Recombinant Proteins - pharmacology
RNA, Messenger - biosynthesis
RNA, Messenger - genetics
U937 Cells - drug effects
Umbilical Veins
Vascular Cell Adhesion Molecule-1 - biosynthesis
Vascular Cell Adhesion Molecule-1 - genetics
Title High-density lipoproteins neutralize C-reactive protein proinflammatory activity
URI https://www.ncbi.nlm.nih.gov/pubmed/15078800
https://search.proquest.com/docview/71897089
Volume 109
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdZB2MwytZuXfbR-WHsJSizLVmyHt0sI-mabKQJ7ZvxhwSGNQmt89D-Ufsbd5Id2yku-3hxgoUtrPvpdLr76Q6hjwQWNUBOjO3EFZimtoeFLRnmcaRil4OFZPIWTKZstKCnl95lp_OrwVra5HE_uWs9V_I_UoV7IFd9SvYfJFu9FG7Af5AvXEHCcP0rGWuSBk41BV3Xf8jWK5N1QZNelnJjXBh3sjfAYBcardYrm_UvdA9YuCpi7KY5y3civIPsOilLe7VV7Gl4EC6CL6Ng0mSPFBA6Owmmw_NhocO1hz6TVePs-8lwNj8veLp1ZP9sfLqY9i6CMsvV1htBDfev9ka2ZZUw3ojsp6b87GhigTkpziT3Zal8XYqpVyQ3qrSzLZow5DvK1mGNhRsWYbd9UWCOOejQH4xnJl-lo3P2iD6FzZTXd1sycd9bISveouOBwQo24iP02AXFZmgB42_Vys8I97aV-_S3lUluof_PD_e-YxA9W0c3MDdVUVTl4V2PsX7mz9F-uW2xggKDL1BHLg_QYbAE_FzdWp8sQyQ2EZoD9GRS8jUO0Y8mQq0mQq0aoVaNUKtstu4h1Noi9CVafB3OByNc1vDAiWezHFMnJcpVVIeTGeURFyKWXpSKyFWEJ2BOSkUjlkowjHXlBZX4riSMJZEXK-k75BXaW66W8jWyuPIViWRkc8VoYhMRe4mvMyuTiKeUyC4i24EM10WqltBscZkT2k4Iwx_Wwx-a4Q9d1kXHO2NeP1rKuos-bIUQgurV8TSYF6vNTQhmneC2L7roqJBN41mwvGEr9uZPL3-Lntaz6B3ay6838j1YuXl8bKD1GzzroVM
link.rule.ids 315,783,787,27936,27937
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=High-density+lipoproteins+neutralize+C-reactive+protein+proinflammatory+activity&rft.jtitle=Circulation+%28New+York%2C+N.Y.%29&rft.au=WADHAM%2C+Carol&rft.au=ALBANESE%2C+Nathaniel&rft.au=ROBERTS%2C+Jane&rft.au=LIJUN+WANG&rft.date=2004-05-04&rft.pub=Lippincott+Williams+%26+Wilkins&rft.issn=0009-7322&rft.eissn=1524-4539&rft.volume=109&rft.issue=17&rft.spage=2116&rft.epage=2122&rft_id=info:doi/10.1161%2F01.CIR.0000127419.45975.26&rft.externalDBID=n%2Fa&rft.externalDocID=15835560
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-7322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-7322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-7322&client=summon